SRPT - サレプタ・セラピュ―ティックス （Sarepta Therapeutics Inc.）

U.S. stocks traded lower, with the Dow Jones … Full story available on Benzinga.com

Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed.

Sarepta Therapeutics (SRPT) stock is heading higher on Wednesday following the release of its latest earnings report and an upgrade.

US-Vorbörse: Kohl''s, Rivian, AMC Entertainment, Sarepta Therapeutics, Novavax und First Solar mit viel Bewegung

https://www.investing.com/news/pro/sarepta-therapeutics-pt-raised-to-180-at-oppenheimer-432SI-3018810

Related Stocks: ENCP , AVGOP.PFD , SRPT , INFN , NEEPO ,

The share price of Sarepta Therapeutics Inc. (NASDAQ:SRPT) rose to $124.47 per share on Thursday from $123.16. While Sarepta Therapeutics Inc. has overperformed by 1.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SRPT rose by 81.15%, with highs and lows ranging from $134.08 to $61.28, […]

Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in a way never seen before. With the potential for vast improvements, gene therapy and gene editing are promising modern biotechnology forms. Despite a precipitous drop in stock prices last year, analysts are still optimistic about the future of gene editing. The incredible possibilities in the gene editing realm open up a remarkably long-term investment opportunity for investors to catch on to for robust upside potential. According to ResearchAndMarkets , the market could grow by 14.7% annually through 2030 to a whopping $19.4 billion. CRSP CRISPR Therapeutics $51.96 GNOM Global X Genomics and Biotechnology ETF $13.63 NTLA Intellia Therapeutics $38.53 CRISPR Therapeutics ( CRSP ) Source: rafapress / Shutterstock.com CRISPR Therapeutics (NASDAQ: CRSP ) is a cutting-edge biotech company dedicated to treating blood disorders and cancer with its revolutionary CRISPR-Cas9 gene-editing tool.

CRISPR could revolutionize the way we treat thousands of diseases. Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material, the Cleveland Clinic reported . Fortunately, CRISPR, or clustered regularly interspaced short palindromic repeats, has the potential to treat most, if not all of these illnesses. In fact, according to Interesting Engineering , “researchers have already identified DNA errors as the cause of nearly 7,000 diseases. Thankfully, the growing world of genome editing could be the ‘spell-checker’ needed to detect and eventually fix these.” So, I went hunting for CRISPR stocks that will make you rich in ten years. CRISPR has shown that it could potentially be used to treat cardiovascular diseases , cancer , and neurogenerative issues, such as Alzheimer’s , Parkinson’s , and even muscular dystrophy . It may even help educe the negative impact of sickle cell anemia , lymphoblastic leukemia , lung cancer , multiple myeloma , Beta thalassemia , and thousands of other illnesses.

Sarepta''s net product revenues for Q4 2022 are expected to come in about 32% higher at $235.5 million. Click here for our recommendation on SRPT stock.

Sarepta Therapeutics sees its Relative Strength Rating reach the 80-plus level.

Keerthi Vedantam / dot.LA : VivoSense, which develops wearable biometric sensors to collect and organize data from patients for clinical drug trials, raises a $25M Series A — As the CEO of Sarepta Therapeutics from 2011 to 2015, Chris Garabedian led a biotech firm striving to find cures for rare diseases.

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications. Academic scholarships of up to $5,000 will be awarded to up to 15 individuals living with Duchenne. Additionally, for the 2022-2023 school year, the program has been expanded and Sarepta will be awarding up to 5 academic scholarships of $5,000 to siblings of individuals living with Duchenne.

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences: